Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1999 1
2000 3
2001 4
2002 4
2003 4
2004 4
2005 8
2006 4
2007 4
2008 4
2009 4
2010 5
2011 4
2012 3
2013 9
2014 3
2015 2
2016 7
2017 11
2018 7
2019 5
2020 8
2021 4
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

101 results
Results by year
Filters applied: . Clear all
Page 1
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.
Wang L, Leite de Oliveira R, Huijberts S, Bosdriesz E, Pencheva N, Brunen D, Bosma A, Song JY, Zevenhoven J, Los-de Vries GT, Horlings H, Nuijen B, Beijnen JH, Schellens JHM, Bernards R. Wang L, et al. Among authors: nuijen b. Cell. 2018 May 31;173(6):1413-1425.e14. doi: 10.1016/j.cell.2018.04.012. Epub 2018 May 10. Cell. 2018. PMID: 29754815 Free article.
Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.
van den Berg JH, Heemskerk B, van Rooij N, Gomez-Eerland R, Michels S, van Zon M, de Boer R, Bakker NAM, Jorritsma-Smit A, van Buuren MM, Kvistborg P, Spits H, Schotte R, Mallo H, Karger M, van der Hage JA, Wouters MWJM, Pronk LM, Geukes Foppen MH, Blank CU, Beijnen JH, Nuijen B, Schumacher TN, Haanen JBAG. van den Berg JH, et al. Among authors: nuijen b. J Immunother Cancer. 2020 Aug;8(2):e000848. doi: 10.1136/jitc-2020-000848. J Immunother Cancer. 2020. PMID: 32753545 Free PMC article. Clinical Trial.
Inherent formulation issues of kinase inhibitors.
Herbrink M, Schellens JH, Beijnen JH, Nuijen B. Herbrink M, et al. Among authors: nuijen b. J Control Release. 2016 Oct 10;239:118-27. doi: 10.1016/j.jconrel.2016.08.036. Epub 2016 Aug 28. J Control Release. 2016. PMID: 27578098 Review.
Alternative formulations of paclitaxel.
Terwogt JM, Nuijen B, Huinink WW, Beijnen JH. Terwogt JM, et al. Among authors: nuijen b. Cancer Treat Rev. 1997 Mar;23(2):87-95. doi: 10.1016/s0305-7372(97)90022-0. Cancer Treat Rev. 1997. PMID: 9225960 Review.
Taxanes: old drugs, new oral formulations.
Jibodh RA, Lagas JS, Nuijen B, Beijnen JH, Schellens JH. Jibodh RA, et al. Among authors: nuijen b. Eur J Pharmacol. 2013 Oct 5;717(1-3):40-6. doi: 10.1016/j.ejphar.2013.02.058. Epub 2013 May 7. Eur J Pharmacol. 2013. PMID: 23660368 Review.
High-Tech Drugs in Creaky Formulations.
Herbrink M, Nuijen B, Schellens JHM, Beijnen JH. Herbrink M, et al. Among authors: nuijen b. Pharm Res. 2017 Sep;34(9):1751-1753. doi: 10.1007/s11095-017-2185-4. Epub 2017 May 30. Pharm Res. 2017. PMID: 28560695
Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial.
Duinkerken CW, de Weger VA, Dreschler WA, van der Molen L, Pluim D, Rosing H, Nuijen B, Hauptmann M, Beijnen JH, Balm AJM, de Boer JP, Burgers JA, Marchetti S, Schellens JHM, Zuur CL. Duinkerken CW, et al. Among authors: nuijen b. Otol Neurotol. 2021 Jun 1;42(5):678-685. doi: 10.1097/MAO.0000000000003069. Otol Neurotol. 2021. PMID: 33710154 Clinical Trial.
Phase I pharmacological study of continuous chronomodulated capecitabine treatment.
Roosendaal J, Jacobs BAW, Pluim D, Rosing H, de Vries N, van Werkhoven E, Nuijen B, Beijnen JH, Huitema ADR, Schellens JHM, Marchetti S. Roosendaal J, et al. Among authors: nuijen b. Pharm Res. 2020 May 7;37(5):89. doi: 10.1007/s11095-020-02828-6. Pharm Res. 2020. PMID: 32382808 Free PMC article. Clinical Trial.
Solubility and bioavailability improvement of pazopanib hydrochloride.
Herbrink M, Groenland SL, Huitema ADR, Schellens JHM, Beijnen JH, Steeghs N, Nuijen B. Herbrink M, et al. Among authors: nuijen b. Int J Pharm. 2018 Jun 10;544(1):181-190. doi: 10.1016/j.ijpharm.2018.04.037. Epub 2018 Apr 19. Int J Pharm. 2018. PMID: 29680279
101 results